R1	Has_qualifier Arg1:T2 Arg2:T3	
R2	Has_qualifier Arg1:T2 Arg2:T4	
R3	Has_negation Arg1:T6 Arg2:T5	
R4	AND Arg1:T2 Arg2:T6	
R5	Subsumes Arg1:T7 Arg2:T8	
R6	Has_qualifier Arg1:T10 Arg2:T9	
*	OR T10 T14 T15 T11 T12 T16 T19 T13
R7	Has_negation Arg1:T21 Arg2:T20	
R8	Has_temporal Arg1:T23 Arg2:T24	
R9	Has_mood Arg1:T23 Arg2:T22	
*	OR T21 T23
R10	Has_qualifier Arg1:T19 Arg2:T18	
R11	Has_qualifier Arg1:T19 Arg2:T21	
*	OR T28 T29
R12	Has_temporal Arg1:T28 Arg2:T30	
R13	Has_temporal Arg1:T32 Arg2:T33	
*	OR T34 T35
R14	AND Arg1:T34 Arg2:T36	
R15	Has_index Arg1:T30 Arg2:T40	
R16	Has_index Arg1:T33 Arg2:T39	
R17	Has_index Arg1:T38 Arg2:T41	
*	OR T42 T43
R18	Has_temporal Arg1:T42 Arg2:T38	
R19	Has_qualifier Arg1:T50 Arg2:T52	
*	OR T47 T48 T49 T50
R20	AND Arg1:T47 Arg2:T51	
R21	AND Arg1:T46 Arg2:T45	
R22	Subsumes Arg1:T46 Arg2:T47	
*	OR T58 T59
R23	Has_mood Arg1:T58 Arg2:T57	
T1	Competing_trial 0 140	Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug.
T2	Condition 165 186	psychiatric diagnosis
T3	Qualifier 157 164	primary
T4	Qualifier 150 156	Axis I
T5	Negation 187 197	other than
T6	Condition 198 223	major depressive disorder
T7	Condition 226 248	Organic mental disease
T8	Condition 260 278	mental retardation
T9	Qualifier 292 314	clinically significant
T10	Condition 315 322	disease
T11	Condition 338 352;426 433	cardiovascular disease
T12	Condition 396 410;426 433	endocrinologic disease
T13	Condition 383 394;426 433	hematologic disease
T14	Condition 370 381;426 433	respiratory disease
T15	Condition 363 368;426 433	renal disease
T16	Condition 354 361;426 433	hepatic disease
T17	Condition 415 433	neurologic disease
T18	Qualifier 438 460	clinically significant
T19	Condition 461 483	laboratory abnormality
T20	Negation 492 495	not
T21	Qualifier 496 506	stabilized
T22	Mood 513 535	anticipated to require
T23	Procedure 536 545	treatment
T24	Temporal 546 562	during the study
T26	Competing_trial 565 730	Subjects receiving an investigational agent (including different formulation and generic agents of investigational drug) in the previous 3 months prior to screening.
T27	Pregnancy_considerations 732 845	Women in pregnancy or lactation, or female of child bearing potential without appropriate birth control measures.
T28	Drug 854 868	antipsychotics
T29	Drug 872 888	mood stabilizers
T30	Temporal 889 921	within 5 days prior to screening
T32	Drug 937 967	depot antipsychotic medication
T33	Temporal 968 1003	within one cycle prior to screening
T34	Condition 1012 1019	allergy
T35	Condition 1023 1039	lack of response
T36	Drug 1043 1054	mirtazapine
T38	Temporal 1082 1116	within 3 months prior to screening
T39	Reference_point 994 1003	screening
T40	Reference_point 912 921	screening
T41	Reference_point 1107 1116	screening
T42	Procedure 1070 1073	ECT
T43	Procedure 1077 1081	MECT
T45	Drug 1130 1150	anticholinergic drug
T46	Condition 1151 1158	allergy
T47	Condition 1177 1194	allergic reaction
T48	Condition 1196 1205	skin rash
T49	Condition 1207 1216	urticaria
T50	Condition 1227 1245	allergic reactions
T51	Drug 1262 1267	drugs
T52	Qualifier 1221 1226	other
T56	Observation 1271 1278	Smokers
T57	Mood 1293 1300	risk of
T58	Observation 1301 1309;1327 1336	suicidal behaviors
T59	Observation 1317 1336	self-harm behaviors
